(Adds AstraZeneca's Canada and Thailand deals, RDIF deals with Uzbekistan, Egypt, India, Nepal and Brazil; Updates Johnson & Johnson's EU agreement) Oct 12 (Reuters) - The United States and United Kingdom are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines. The European Union also struck its first supply deal with AstraZeneca in August, and has signed two more with Johnson & Johnson and Sanofi since then. The following is a list of supply deals that give some countries a guarantee of a limited number of doses: COUNTRY/REGIO COMPANY DEAL TERM NO OF DOSES DELIVERY DATE STORY LINK N U.S. Moderna Inc $1.53 bln 100 mln + option for additional Not specified 400 mln U.S. Pfizer Inc and $1.95 bln 100 mln + option for 500 mln By October BioNTech SE more U.S. AstraZeneca Plc $1.2 bln 300 mln By October U.S. Novavax Inc $1.6 bln 100 mln By January 2021 U.S. Johnson & Johnson Over $1 bln 100 mln + 200 mln more under Not Specified subsequent agreement U.S. Sanofi SA and $2.1 bln 100 mln + option for 500 mln Not Specified GlaxoSmithKline Plc more EU AstraZeneca 336 mln euros At least 300 mln + 100 mln Not specified ($396 mln) additional EU Johnson & Johnson Undisclosed 200 mln + 200 mln additional Not Specified EU Sanofi SA and 324 mln euros 300 mln Not Specified GlaxoSmithKline ($384 mln) EU Moderna In talks 80 mln Not Specified EU CureVac In talks 225 mln + option for 180 mln Not Specified additional EU BioNTech/ Pfizer Concluded 200 mln + 100 mln additional Not Specified exploratory talks EU ReiThera In early talks Not specified Not specified Italy, AstraZeneca 750 mln euros 300 mln + 100 mln additional Not Applicable Germany, the ($843 million) Netherlands and France UK Johnson & Johnson Non-profit basis 30 mln + option for up to 22 Not specified for emergency use; mln more option to purchase additional doses UK Novavax Not specified 60 mln, and plan for a By early 2021; phase 3 late-stage trial in UK with trial in Q3 2020 govt support UK Valneva "Multi-million 60 mln + 40 mln additional Not Applicable pound" investment UK Sanofi , Financial terms Up to 60 mln Not Applicable GlaxoSmithKline undisclosed UK Pfizer and BioNTech Financial terms 30 mln Not Applicable undisclosed UK AstraZeneca 65.5 mln pounds in Up to 30 mln (part of a September total commitment to deliver 100 mln total) Canada Pfizer and BioNTech Financial details Not specified Over the course of 2021 not disclosed Canada Moderna Not specified Not specified Not Specified Canada Johnson & Johnson Not specified Up to 38 mln Not specified Canada AstraZeneca Not specified Up to 20 mln Not specified Canada Novavax Not specified Up to 76 mln Q2 of 2021 Japan Moderna In talks 40 mln or more, to be H1 of 2021 distributed by Takeda Japan Pfizer and BioNTech Financial details 120 mln H1 of 2021 were not disclosed Japan Johnson & Johnson In talks Not Applicable Not Applicable Japan AstraZeneca Co-production with 120 mln First 30 mln expected by JCR Pharma March 2021 , Daiichi Sankyo Biotech and KM Biologics Japan Novavax Co-production with 250 mln Production is yearly Takeda estimate Europe, Latin Arcturus Therapeutics In talks Not Applicable Not Applicable America and Holdings Inc Southeast Asia Israel Arcturus Therapeutics $275 million Initial one mln Not Applicable Holdings Inc Israel Moderna Financial terms Not Applicable Not Applicable were not disclosed Indonesia Sinovac Biotech Ltd Financial terms At least 40 mln By March 2021 were not disclosed China AstraZeneca Produced by At least 200 mln By end 2021 Shenzhen Kangtai Biological Products Thailand AstraZeneca Not disclosed Not disclosed Mid-year 2021 Uzbekistan Russia's sovereign fund, Not disclosed Up to 35 million Not applicable RDIF Egypt RDIF Not disclosed 25 million Not applicable India RDIF Not disclosed 100 million Not applicable Nepal RDIF Not disclosed 25 million Not applicable Brazil Gamaleya Research Institute Not disclosed Brazil's Bahia state to get 50 To start in November and RDIF mln and will conduct Phase 3 clinical trials Brazil AstraZeneca $356 mln to buy 100 mln December/January and produce the vaccine Mexico Gamaleya, RDIF Financial terms 32 mln November not specified Mexico, AstraZeneca To produce the 150 mln + up to 250 mln more First half of 2021 Argentina vaccine for most of Latin America ($1 = 0.8484 euros) (Reporting by Mrinalika Roy, Manojna Madippatla, Trisha Roy and Manas Mishra in Bengaluru, Rocky Swift in Tokyo; Editing by Sriraj Kalluvila, Shounak Dasgupta, Aditya Soni, Vinay Dwivedi and Ramakrishnan M.)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.